Ken Fisher's NVO Position Overview
Ken Fisher (via Fisher Asset Management, LLC) currently holds 10.32 M shares of Novo Nordisk A/S (NVO) worth $572.82 M, representing 0.21% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Ken Fisher has maintained a long-term strategic position in NVO, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2017, adding 2.66 M shares. Largest reduction occurred in Q3 2022, reducing 9.97 M shares.
Analysis based on 13F filings available since 2013 Q2
Ken Fisher's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Ken Fisher
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +26.91 M | Add 0.00% | 26.91 M | $15.50 |
| Q3 2013 | +115,500 | Add 0.43% | 27.03 M | $16.92 |
| Q4 2013 | +56,260 | Add 0.21% | 27.08 M | $18.48 |
| Q1 2014 | +179,288 | Add 0.66% | 27.26 M | $22.83 |
| Q2 2014 | +219,100 | Add 0.80% | 27.48 M | $23.09 |
| Q3 2014 | -711,232 | Reduce 2.59% | 26.77 M | $23.81 |
| Q4 2014 | -692,530 | Reduce 2.59% | 26.08 M | $21.16 |
| Q1 2015 | -758,826 | Reduce 2.91% | 25.32 M | $26.70 |
| Q2 2015 | -728,742 | Reduce 2.88% | 24.59 M | $27.38 |
| Q3 2015 | -1.29 M | Reduce 5.23% | 23.3 M | $27.12 |
| Q4 2015 | -409,710 | Reduce 1.76% | 22.89 M | $29.04 |
| Q1 2016 | -537,208 | Reduce 2.35% | 22.36 M | $28.07 |
| Q2 2016 | -431,430 | Reduce 1.93% | 21.93 M | $27.68 |
| Q3 2016 | -104,850 | Reduce 0.48% | 21.82 M | $20.80 |
| Q4 2016 | -578,262 | Reduce 2.65% | 21.24 M | $17.93 |
| Q1 2017 | -525,066 | Reduce 2.47% | 20.72 M | $17.14 |
| Q2 2017 | +2.66 M | Add 12.86% | 23.38 M | $21.45 |
| Q3 2017 | +867,454 | Add 3.71% | 24.25 M | $24.08 |
| Q4 2017 | +1.16 M | Add 4.79% | 25.41 M | $26.84 |
| Q1 2018 | +848,360 | Add 3.34% | 26.26 M | $24.63 |
| Q2 2018 | +880,028 | Add 3.35% | 27.14 M | $23.06 |
| Q3 2018 | +455,466 | Add 1.68% | 27.59 M | $23.57 |
| Q4 2018 | +811,062 | Add 2.94% | 28.41 M | $23.03 |
| Q1 2019 | +753,474 | Add 2.65% | 29.16 M | $26.16 |
| Q2 2019 | +643,124 | Add 2.21% | 29.8 M | $25.52 |
| Q3 2019 | +620,132 | Add 2.08% | 30.42 M | $25.85 |
| Q4 2019 | -246,216 | Reduce 0.81% | 30.18 M | $28.94 |
| Q1 2020 | +473,726 | Add 1.57% | 30.65 M | $30.10 |
| Q2 2020 | +315,554 | Add 1.03% | 30.97 M | $32.74 |
| Q3 2020 | +440,988 | Add 1.42% | 31.41 M | $34.72 |
| Q4 2020 | +251,048 | Add 0.80% | 31.66 M | $34.92 |
| Q1 2021 | +451,690 | Add 1.43% | 32.11 M | $33.71 |
| Q2 2021 | +54,584 | Add 0.17% | 32.16 M | $41.88 |
| Q3 2021 | +187,104 | Add 0.58% | 32.35 M | $48.01 |
| Q4 2021 | -473,216 | Reduce 1.46% | 31.88 M | $56.00 |
| Q1 2022 | -55,658 | Reduce 0.17% | 31.82 M | $55.53 |
| Q2 2022 | -3.18 M | Reduce 10.00% | 28.64 M | $55.72 |
| Q3 2022 | -9.97 M | Reduce 34.82% | 18.67 M | $49.81 |
| Q4 2022 | -613,722 | Reduce 3.29% | 18.05 M | $67.67 |
| Q1 2023 | -2.3 M | Reduce 12.75% | 15.75 M | $79.57 |
| Q2 2023 | -510,072 | Reduce 3.24% | 15.24 M | $80.92 |
| Q3 2023 | -491,657 | Reduce 3.23% | 14.75 M | $90.94 |
| Q4 2023 | -618,485 | Reduce 4.19% | 14.13 M | $103.45 |
| Q1 2024 | -404,880 | Reduce 2.87% | 13.72 M | $128.40 |
| Q2 2024 | -354,091 | Reduce 2.58% | 13.37 M | $142.74 |
| Q3 2024 | -65,153 | Reduce 0.49% | 13.31 M | $119.07 |
| Q4 2024 | -664,985 | Reduce 5.00% | 12.64 M | $86.02 |
| Q1 2025 | -769,253 | Reduce 6.09% | 11.87 M | $69.44 |
| Q2 2025 | -870,320 | Reduce 7.33% | 11 M | $69.02 |
| Q3 2025 | -678,013 | Reduce 6.16% | 10.32 M | $55.49 |
Ken Fisher's Novo Nordisk A/S Investment FAQs
Ken Fisher first purchased Novo Nordisk A/S (NVO) in Q2 2013, acquiring 26,912,910 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ken Fisher has held Novo Nordisk A/S (NVO) for 50 quarters since Q2 2013.
Ken Fisher's largest addition to Novo Nordisk A/S (NVO) was in Q2 2013, adding 26,912,910 shares worth $417.07 M.
According to the latest 13F filing for Q3 2025, Ken Fisher's firm, Fisher Asset Management, LLC, owns 10,322,903 shares of Novo Nordisk A/S (NVO), valued at approximately $572.82 M.
As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.21% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.
Ken Fisher's peak holding in Novo Nordisk A/S (NVO) was 32,351,078 shares, as reported at the end of Q3 2021.